The pharmacy as an on-demand production lab is no longer a distant vision. CurifyLabs, a young Finnish company founded in 2021, has just closed a €12 million Series A round co-led by Sandwater and HealthCap, with participation from Tesi, Lifeline Ventures, and US-based investors. The goal is to scale a system that lets pharmacists prepare personalized medicines with the same logic used to manage on-premise IT workloads: direct control, repeatability, and built-in quality.

At the heart of the technology is a Compounding System Solution that integrates proprietary software, GMP-manufactured excipient bases, and three-dimensional printing. The result is an automated compounding process with integrated quality control that promises to reduce variability and increase speed and precision compared to traditional manual methods. The company already has broad reach: pharmacies in twenty-one US states and across Europe use its solutions to dose active ingredients, release profiles, and custom combinations for individual patients.

As adoption grows, CurifyLabs will use part of the new capital to strengthen its supply chain and customer support, while also accelerating development of the PharmaPrinter Aurum, the platform's latest product. CEO and founder Charlotta Topelius noted that the funding reflects partners' confidence in the path they are building, setting an ambitious bar for clinical rigor, product quality, and support.

For those tracking the evolution of local infrastructure in healthcare, CurifyLabs' move sends a clear signal. Manufacturing personalized medicines directly inside a pharmacy keeps sensitive patient data within a controlled perimeter, reducing exposure to cloud-centric models and the compliance risks that trouble many IT decision-makers. While this isn't about compute loads for Large Language Models, the principles of sovereignty, operational resilience, and full-stack control – software, hardware (the printing device), consumables – align with the most thoughtful on-premise strategies. Automation isn't just about efficiency: here it builds a local production chain that could inspire sectors where personalization and privacy are just as critical.